Piperazine derivative

• Main Authors: HOSOGAI NAOMI, TANABE DAISUKE, MIHARA HISASHI, MORITOMO HIROYUKI, YAMASHITA DAISUKE, YONETOKU YASUHIRO, OSODA KAZUHIKO, ASAI NORIO, SUGANE TAKASHI, MAENO KYOICHI, SUGASAWA KEIZO, SHIMIZU TAKAFUMI, MAKINO TAKUYA
• Format: Patent
• Language: Chinese; English
• Published: 27.03.2018
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention provides a compound that can be used as an MC4 receptor agonist. The inventors study MC4 receptor agonists, and confirm that a piperazine derivative has an action, thereby perfecting the present invention. Specifically, this piperazine derivative has an MC4 receptor agonist action and can be used as an agent for the prevention and/or treatment of bladder and urinary tract diseases, especially underactive bladder, hypotonic bladder, noncontracting bladder, detrusor muscle hypoactivity, neurogenic bladder, urethral relaxation failure, detrusor-external sphincter incoordination, and dysuria in benign prostatic hyperplasia. 本发明提供能够作为MC受体激动剂使用的化合物。本发明人对MC受体激动剂进行了研究，确认了哌嗪衍生物具有作用，从而完成了本发明。即，本发明的哌嗪衍生物具有MC受体激动剂作用，能够作为膀胱和尿路系统疾病、特别是膀胱活动低下、低张力性膀胱、无收缩膀胱、逼尿肌活动低下、神经源性膀胱、尿道松弛不全、逼尿肌尿道外括约肌协同失调和前列腺肥大症中的排尿障碍的预防和/或治疗剂使用。